LLY · 8-K · 20260805PR000077

Asset Impairment and Restructuring Charges

ELI LILLY & Co · 2026-08-05 · Importance 65 · Surprise 82

Lilly recognized $703 million of asset impairment, restructuring, and other special charges in Q2 2026, compared with no such charges in Q2 2025.,The charges primarily reflected accelerated vesting of employee equity awards and acquisition and integration costs associated with Kelonia Therapeutics and Centessa Pharmaceuticals.,Six-month charges totaled $982 million, compared with $35 million in the first half of 2025.,The Q2 charges reduced reported EPS by $0.72 and were excluded from non-GAAP net income.

Key facts

• Q2 2026 asset impairment, restructuring and other special charges were $703 million, primarily related to accelerated vesting of employee equity awards and other acquisition and integration costs associated with Kelonia Therapeutics, Inc. and Centessa Pharmaceuticals plc acquisitions. source
• Asset impairment, restructuring and other special charges for six months ended June 30, 2026 were $982 million compared with $35 million in six months ended June 30, 2025. source